Black Diamond Therapeutics shares rise 1.75% premarket after reporting a narrower Q2 net loss and exploring partnerships for silevertinib development.
ByAinvest
Friday, Aug 8, 2025 4:15 am ET1min read
BDTX--
Black Diamond Therapeutics, Inc. rose 1.75% in premarket trading. The company reported a narrowing of its Q2 net loss to $10.6 million from $19.9 million year-over-year, and it is exploring partnerships to advance the development of silevertinib in NSCLC and GBM. The company expects to release Q4 2025 data for the silevertinib Phase 2 trial and plans an FDA meeting in the first half of 2026 for the NSCLC path. Additionally, Black Diamond is exploring partnerships for the pivotal development of silevertinib and sees cash funding operations into Q4 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet